stockrowArcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
Follow RCUS
Alert me
Arcus Biosciences, Inc. (RCUS) Operating cash flow
Arcus Biosciences, Inc.'s operating cash flow for fiscal 2025 was −$482.0M, compared with −$170.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$465.0M. Over the past ten years it has ranged from −$482.0M (fiscal 2025) to $438.0M (fiscal 2022) — the current reading is the lowest in ten years. Arcus Biosciences, Inc. ranks 592nd of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$482.0M | — |
| FY2024 | −$170.0M | — |
| FY2023 | −$306.0M | — |
| FY2022 | $438.0M | — |
| FY2021 | −$256.0M | — |
| FY2020 | $111.0M | — |
| FY2019 | −$73.5M | — |
| FY2018 | −$43.0M | — |
| FY2017 | −$25.1M | — |
| FY2016 | −$12.9M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$88.0M | — |
| Jun 2026 | −$119.0M | — |
| Mar 2026 | −$138.0M | — |
| Dec 2025 | −$120.0M | — |
| 36 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| MBX MBX Biosciences, Inc. compare | −$82.7M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.5M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$159.2M |
| PHVS Pharvaris N.V. compare | −$178.0M |
| XNCR Xencor, Inc. compare | −$205.8M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$310.5M |
| IDYA IDEAYA Biosciences, Inc. compare | −$347.4M |
| BEAM Beam Therapeutics Inc. compare | −$388.6M |
| RCUS Arcus Biosciences, Inc. | −$465.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on RCUS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement